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Along with the wide use of pesticides in the world, the concerns over their health impacts are rapidly grow-
ing. There is a huge body of evidence on the relation between exposure to pesticides and elevated rate of
chronic diseases such as different types of cancers, diabetes, neurodegenerative disorders like Parkinson,
Alzheimer, and amyotrophic lateral sclerosis (ALS), birth defects, and reproductive disorders. There is also
circumstantial evidence on the association of exposure to pesticides with some other chronic diseases like
respiratory problems, particularly asthma and chronic obstructive pulmonary disease (COPD), cardiovascular
disease such as atherosclerosis and coronary artery disease, chronic nephropathies, autoimmune diseases like
systemic lupus erythematous and rheumatoid arthritis, chronic fatigue syndrome, and aging. The common
feature of chronic disorders is a disturbance in cellular homeostasis, which can be induced via pesticides' pri-
mary action like perturbation of ion channels, enzymes, receptors, etc., or can as well be mediated via path-
ways other than the main mechanism. In this review, we present the highlighted evidence on the association
of pesticide's exposure with the incidence of chronic diseases and introduce genetic damages, epigenetic
modiﬁcations, endocrine disruption, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum
stress and unfolded protein response (UPR), impairment of ubiquitin proteasome system, and defective
autophagy as the effective mechanisms of action.
© 2013 Elsevier Inc. All rights reserved.
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